Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chloroquine or pharmaceutically acceptable salt thereof in preparation of medicine for treating or/and preventing liver cancer

A technology for inhibiting liver cancer and drugs, applied in the application field of preparing drugs for treating or/or preventing liver cancer, can solve the problems of inability to remove the cause, the molecular mechanism of the cause and pathogenesis is not completely clear, and there is no satisfactory prevention.

Inactive Publication Date: 2020-10-30
TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

but it does not remove the cause
Although significant progress has been made in conventional treatment options for patients with HCC, there are currently no satisfactory methods for prevention, diagnosis, and treatment due to the incomplete understanding of the etiology and molecular mechanisms of pathogenesis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chloroquine or pharmaceutically acceptable salt thereof in preparation of medicine for treating or/and preventing liver cancer
  • Application of chloroquine or pharmaceutically acceptable salt thereof in preparation of medicine for treating or/and preventing liver cancer
  • Application of chloroquine or pharmaceutically acceptable salt thereof in preparation of medicine for treating or/and preventing liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Embodiment 1, chloroquine enhanced the anti-liver cancer activity of 7-deoxynarcicycline

[0058] 1. Preparation of the medicine named 7-deoxynarcicycline+CQ for the treatment or / and prevention of liver cancer

[0059] This embodiment provides a drug for treating or / and preventing liver cancer (abbreviated as 7-deoxynarcicycline+CQ), the active ingredients of which are chloroquine phosphate and 7-deoxynarcicycline, which can treat or / and prevent liver cancer In the medicine, the mass ratio of chloroquine phosphate and 7-deoxynarcicycline is 1:20. The preparation method of the medicine for treating or / and preventing liver cancer is as follows:

[0060] 1.1 Preparation of 7-deoxynarcicycline solution

[0061] 7-Deoxynarcicycline was prepared as a 10 mM stock solution by dissolving in dimethyl sulfoxide (DMSO), and stored in aliquots at -20°C, and diluted to the corresponding concentration with normal saline to obtain 7-deoxynarcicycline solution.

[0062] 1.2 Preparat...

Embodiment 2、7

[0075] Example 2, 7-deoxynarcicycline anti-liver cancer activity

[0076] 1. 7-Deoxynarcicycline inhibits the growth of hepatocellular carcinoma and promotes the apoptosis of hepatocellular carcinoma

[0077] Cell viability was measured by MTT assay, and the growth inhibitory effect of 7-deoxynarcicycline on two typical human liver cancer cell lines (HepG2, Huh-7) was analyzed. The HepG2 and Huh-7 cells were planted in the logarithmic growth phase, and then treated with 10 μM 7-deoxynarcicycline. After 0, 12, 24, 48, and 72 hours, the cell viability was measured by the MTT method. The results showed that 10 μM 7-deoxynarcicycline was treated for 0, 12, 24, 48, and 72 hours, and the viability of liver cancer cells had a time-dependent downward trend ( Figure 4 ). The HepG2 and Huh-7 treated with 7-deoxynarcicycline for 48 hours were tested for monoclonal formation experiments. The results showed that 7-deoxynarcicycline treated HepG2 and Huh-7 for 48 hours could significantl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of chloroquine or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating or / and preventing liver cancer. The medicine for treating or / and preventing liver cancer contains A and B, wherein A is chloroquine or the pharmaceutically acceptable salt thereof, and the B is 7-deoxynarciclasine or a pharmaceutically acceptable salt thereof.Experimental results proove that the medicine for treating or / and preventing the liver cancer has a remarkable treatment or / and prevention effect on the liver cancer; chloroquine phosphate significantly enhances the anti-hepatoma activity of 7-deoxynarciclasine, 7-deoxynarciclasine significantly enhances the anti-hepatoma activity of chloroquine phosphate, and the chloroquine phosphate and the 7-deoxynarcissus cycline generate a synergistic effect in the anti-hepatoma aspect.

Description

technical field [0001] The invention relates to the application of chloroquine or a pharmaceutically acceptable salt thereof in the preparation of medicines for treating or / and preventing liver cancer in the field of medicine. Background technique [0002] Hepatocellular carcinoma (HCC) refers to cancer that occurs in the liver and is one of the most common aggressive tumors worldwide. Liver cancer is a highly fatal cancer, mainly because of its high degree of malignancy and rapid disease progression, and patients generally do not feel discomfort in the early stage, but once symptoms appear, it is often in the middle and late stages. Therefore, the treatment is difficult and the curative effect is poor. Generally, the survival time after the onset is only 6 months, which is called "the king of cancer". Due to the above reasons, the current treatment strategies for liver cancer are unsatisfactory, mainly including resection, transplantation, local ablation and chemotherapy, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/47A61K31/4741A61P35/00
CPCA61K31/47A61K31/4741A61P35/00A61K2300/00
Inventor 于海洋庞旭邱玉玲王涛尹双双具三虎高秀梅刘二伟韩立峰
Owner TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com